Dr. Chris Brereton outlined current and upcoming research trials in interstitial lung disease (ILD) being conducted in Wessex. Current trials included EME-TIPAC studying the efficacy of co-trimoxazole in IPF patients, MA39189 studying pirfenidone in unclassified fibrosis, and an exercise feasibility study in IPF patients. Upcoming trials included Zephyr studying GBT-440 in hypoxemic IPF patients, Celegene evaluating CC-90001 in IPF, IPF JES measuring asbestos exposure in IPF patients, and TRAIL1 studying pirfenidone in rheumatoid arthritis-ILD. Dr. Brereton provided details on eligibility criteria and study